Solid Biosciences Inc. Payments for (Proceeds from) Available-for-sale Securities, Short-term
Solid Biosciences Inc. (SLDB) reported Payments for (Proceeds from) Available-for-sale Securities, Short-term of -$146.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm · last filed 2026-08-06
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2026-06-30 was -$18.50M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2026-03-31 was -$128.38M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2025-12-31 was -$71.50M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for the quarter ending 2025-09-30 was -$38.00M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for fiscal 2025 was -$178.50M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for fiscal 2024 was -$188.90M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for fiscal 2023 was -$128.63M.
- Solid Biosciences Inc. payments for (proceeds from) available-for-sale securities, short-term for fiscal 2022 was -$212.81M.
| Period end | Payments for (Proceeds from) Available-for-sale Securities, Short-term 3 month | Payments for (Proceeds from) Available-for-sale Securities, Short-term 6 month | Payments for (Proceeds from) Available-for-sale Securities, Short-term 9 month | Payments for (Proceeds from) Available-for-sale Securities, Short-term 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$146.88M 10-Q · filed 2026-08-06 | -$218.38M derived: sum of 3 quarters · filed 2026-08-06 | -$256.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$128.38M 10-Q · filed 2026-05-12 | -$199.88M derived: sum of 2 quarters · filed 2026-05-12 | -$237.88M derived: sum of 3 quarters · filed 2026-05-12 | -$268.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$71.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$109.50M derived: sum of 2 quarters · filed 2026-03-19 | -$140.50M derived: sum of 3 quarters · filed 2026-08-06 | -$178.50M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$38.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$69.00M derived: sum of 2 quarters · filed 2026-08-06 | -$107.00M 10-Q · filed 2025-11-03 | -$161.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$31.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$69.00M 10-Q · filed 2026-08-06 | -$123.10M derived: sum of 3 quarters · filed 2026-08-06 | -$197.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$38.00M 10-Q · filed 2026-05-12 | -$92.10M derived: sum of 2 quarters · filed 2026-05-12 | -$166.60M derived: sum of 3 quarters · filed 2026-05-12 | -$181.90M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$54.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$128.60M derived: sum of 2 quarters · filed 2026-03-19 | -$143.90M derived: sum of 3 quarters · filed 2026-03-19 | -$188.90M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$74.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$89.80M derived: sum of 2 quarters · filed 2025-11-03 | -$134.80M 10-Q · filed 2025-11-03 | -$194.80M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$15.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$60.30M 10-Q · filed 2025-08-12 | -$120.30M derived: sum of 3 quarters · filed 2025-08-12 | -$130.30M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$45.00M 10-Q · filed 2025-05-15 | -$105.00M derived: sum of 2 quarters · filed 2025-05-15 | -$115.00M derived: sum of 3 quarters · filed 2025-05-15 | -$135.87M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$70.00M derived: sum of 2 quarters · filed 2025-03-06 | -$90.87M derived: sum of 3 quarters · filed 2025-03-06 | -$128.63M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$30.87M derived: sum of 2 quarters · filed 2024-11-06 | -$68.63M 10-Q · filed 2024-11-06 | -$123.68M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$20.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$58.63M 10-Q · filed 2024-08-13 | -$113.68M derived: sum of 3 quarters · filed 2024-08-13 | -$179.29M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$37.77M 10-Q · filed 2024-05-15 | -$92.81M derived: sum of 2 quarters · filed 2024-05-15 | -$158.42M derived: sum of 3 quarters · filed 2024-05-15 | -$203.77M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$55.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$120.66M derived: sum of 2 quarters · filed 2024-03-13 | -$166.00M derived: sum of 3 quarters · filed 2024-03-13 | -$212.81M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$65.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$110.96M derived: sum of 2 quarters · filed 2023-11-08 | -$157.77M 10-Q · filed 2023-11-08 | -$205.28M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$45.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$92.16M 10-Q · filed 2023-08-14 | -$139.67M derived: sum of 3 quarters · filed 2024-03-13 | |
| 2022-03-31 | -$46.81M 10-Q · filed 2023-05-11 | -$94.32M derived: sum of 2 quarters · filed 2024-03-13 | ||
| 2021-12-31 | -$47.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$51.44M 10-K · filed 2024-03-13 | ||
| 2021-09-30 | -$3.93M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | -$400.00K derived: sum of 3 quarters · filed 2023-03-23 | -$7.90M 10-K · filed 2023-03-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$400.00K derived: sum of 2 quarters · filed 2021-11-03 | -$7.90M 10-Q · filed 2021-11-03 | -$11.40M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$7.90M 10-Q · filed 2021-08-16 | -$11.40M derived: sum of 3 quarters · filed 2022-03-14 | -$24.95M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | -$7.50M 10-Q · filed 2021-05-14 | -$11.00M derived: sum of 2 quarters · filed 2022-03-14 | -$24.55M derived: sum of 3 quarters · filed 2022-03-14 | -$56.98M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$17.05M derived: sum of 2 quarters · filed 2022-03-14 | -$49.48M derived: sum of 3 quarters · filed 2022-03-14 | -$60.40M 10-K · filed 2022-03-14 |
| 2019-09-30 | -$13.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$45.98M derived: sum of 2 quarters · filed 2020-11-05 | -$56.90M 10-Q · filed 2020-11-05 | -$62.65M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | -$32.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$43.35M 10-Q · filed 2020-08-06 | -$49.10M derived: sum of 3 quarters · filed 2021-03-15 | -$55.24M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | -$10.92M 10-Q · filed 2020-05-07 | -$16.67M derived: sum of 2 quarters · filed 2021-03-15 | -$22.82M derived: sum of 3 quarters · filed 2021-03-15 | -$27.75M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | -$5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$11.89M derived: sum of 2 quarters · filed 2021-03-15 | -$16.83M derived: sum of 3 quarters · filed 2021-03-15 | -$25.34M 10-K · filed 2021-03-15 |
| 2018-09-30 | -$6.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$11.08M derived: sum of 2 quarters · filed 2019-11-12 | -$19.59M 10-Q · filed 2019-11-12 | -$24.86M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$4.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$13.44M 10-Q · filed 2019-08-14 | -$18.71M derived: sum of 3 quarters · filed 2020-03-12 | -$23.63M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$8.51M 10-Q · filed 2019-05-13 | -$13.78M derived: sum of 2 quarters · filed 2020-03-12 | -$18.70M derived: sum of 3 quarters · filed 2020-03-12 | -$32.92M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$10.19M derived: sum of 2 quarters · filed 2020-03-12 | -$24.41M derived: sum of 3 quarters · filed 2020-03-12 | -$31.62M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$19.14M derived: sum of 2 quarters · filed 2018-11-13 | -$26.35M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$14.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$21.43M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$7.21M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$22.04M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |